Misseners disease
Meniere's disease is a disorder of the inner ear characterized by episodes of vertigo, fluctuating sensorineural hearing loss, tinnitus, and a sense of fullness in the affected ear. It results from endolymphatic hydrops - excess fluid buildup in the membranous labyrinth. Episodes typically last 20 minutes to several hours and can be debilitating.
Searching sources...
Reading File
Searching the Web
Meniere's disease diagnosis treatment 2025
Finding Sources
Searching Images
Meniere's disease endolymphatic hydrops inner ear anatomy
Searching PubMed
"Meniere disease"[MeSH Terms] AND treatment
Reading File
Searching Images
Meniere disease endolymphatic hydrops inner ear diagram
Reading File
Reading File
Reading File
Now I have comprehensive information from authoritative sources. Let me compile the full answer.
Meniere's Disease (Ménière's Disease)
Definition
Meniere's disease (MD) is a disorder of the inner ear characterized by the classic tetrad of:
- Episodic vertigo - attacks lasting 30 minutes to 2 hours
- Fluctuating sensorineural hearing loss (SNHL) - typically low-frequency, low-tone
- Tinnitus - fluctuating, usually unilateral
- Aural fullness - sensation of pressure or fullness in the affected ear
The underlying pathology is endolymphatic hydrops - excess fluid accumulation in the membranous labyrinth of the inner ear.
Epidemiology & Natural History
- Affects one ear in 85% of patients
- If the second ear becomes involved, it typically does so within 36 months
- Spontaneous remission occurs in approximately 60% of patients, but cannot be predicted
- Onset is usually in the 4th-5th decade; no strong sex predilection
Pathophysiology
The core defect is endolymphatic hydrops: abnormal distension of the endolymphatic compartment due to impaired reabsorption or overproduction of endolymph. Contributing factors include:
- Immune dysfunction (autoimmune mechanisms are increasingly implicated)
- Viral/inflammatory injury to the endolymphatic sac
- Anatomical obstruction of endolymphatic drainage
- Possible genetic predisposition
During an attack, rupture of Reissner's membrane allows potassium-rich endolymph to flood the perilymphatic space, causing hair cell dysfunction.
Clinical Variants
| Variant | Features |
|---|---|
| Cochlear hydrops | Fluctuating SNHL + tinnitus, no vertigo |
| Vestibular hydrops | Episodic vertigo + aural fullness, no hearing loss |
| Lermoyez syndrome | Worsening tinnitus/hearing loss relieved AFTER a vertigo attack |
| Tumarkin crisis (drop attack) | Sudden loss of extensor muscle tone, fall to ground, no loss of consciousness - occurs late in disease; no warning |
Diagnosis
Diagnosis is clinical, based on history and audiometry. There is no single confirmatory test.
Diagnostic criteria require:
- Two or more definitive spontaneous vertigo episodes (20 min - 12 hours)
- Audiometrically documented low-to-mid frequency SNHL in the affected ear on at least one occasion
- Fluctuating aural symptoms (fullness, tinnitus, or hearing change) in the affected ear
- Not better accounted for by another diagnosis
Investigations:
- Audiometry: Fluctuating low-tone SNHL; little or no tone decay
- ENG/VNG: Often normal between attacks; spontaneous nystagmus during attacks (may show direction-changing components even during caloric testing)
- Glycerol test: Oral glycerol (1.2 mL/kg) - transient improvement in hearing, tinnitus, and fullness within 1-3 hours suggests endolymphatic hydrops; diagnostic utility
- MRI: To exclude acoustic neuroma, other retrocochlear pathology
- Electrocochleography (ECochG): Elevated SP/AP ratio suggests hydrops
Treatment
There is no cure. Treatment aims to reduce frequency and severity of attacks and preserve hearing.
Conservative / Medical (First-Line)
| Approach | Details |
|---|---|
| Low-salt diet | <2 g sodium/day; reduces endolymphatic pressure |
| Diuretics | Hydrochlorothiazide, acetazolamide - reduce endolymph production |
| Vestibular suppressants | Meclizine, promethazine, benzodiazepines - for acute attacks |
| Vasodilators | Betahistine (widely used; improves cochlear microcirculation) |
| Lifestyle | Avoid caffeine, alcohol, tobacco; stress reduction |
Intratympanic Therapy (Second-Line)
Intratympanic dexamethasone (IT steroids)
- Supported by immune dysfunction hypothesis
- Protocol: Dexamethasone 4-24 mg/mL, daily or weekly injections
- ~80% vertigo relief in some studies; avoidance of ablative surgery in 81-91% of patients when used as needed
- Minimal hearing risk
- A 2026 systematic review of RCTs (Martínez et al., Eur Arch Otorhinolaryngol) confirmed efficacy for vertigo control
- A 2025 meta-analysis on IT gentamicin (Devantier et al., Acta Otolaryngol) also evaluated ablative IT therapy outcomes
Intratympanic gentamicin (IT gentamicin)
- Aminoglycoside - selectively ablates vestibular hair cells (chemical labyrinthectomy)
- Highly effective for vertigo control (>85%)
- Risk: hearing loss (dose-dependent)
- Delivered via injection, Silverstein MicroWick, or round window microcatheter
Noninvasive Procedures
- Meniett device: Low-pressure micropulse generator via tympanostomy tube; delivers intermittent positive pressure to middle ear; second-line when medications fail; modest evidence
Surgical Options (Refractory Cases)
| Surgery | Indication | Notes |
|---|---|---|
| Endolymphatic sac decompression/shunt | Useful hearing present | Hearing-preserving; decompresses the sac |
| Selective vestibular neurectomy | Useful hearing, failed conservative Rx | Retrolabyrinthine or retrosigmoid approach |
| Labyrinthectomy | No useful hearing, disabling vertigo | Definitive; abolishes vestibular function |
| Cochleosacculotomy | Elderly, disabling vertigo, poor hearing | Performed under local anesthesia |
Prognosis & Progression
- A 2025 meta-analysis (Hudson et al., Otol Neurotol) found a significant long-term risk of progression from unilateral to bilateral disease - important for counseling
- Hearing loss tends to be progressive and eventually permanent in the affected frequency range despite treatment
- Vertigo attacks often become less frequent over time (burnout), but hearing loss and tinnitus may persist
Emerging Therapy
SPI-1005 (ebselen) - An investigational drug targeting neuroinflammation, granted FDA Breakthrough Therapy designation in December 2025. Phase 3 data showed positive results for hearing loss, tinnitus, and vertigo in Meniere's disease. This represents the most promising pipeline drug to date.
Sources: Cummings Otolaryngology Head and Neck Surgery; K.J. Lee's Essential Otolaryngology; Bradley and Daroff's Neurology in Clinical Practice; Devantier et al. [PMID 40421807]; Hudson et al. [PMID 40210232]; Martínez et al. [PMID 41241712]; Hearing Health Foundation
This is a shared conversation. Sign in to Orris to start your own chat.